Explore Latest Clinical Trials News With Medical Device Insights

Auxilius Pharma Announces Top-line Results of its First-in-Human Clinical Study into the Pharmacokinetics, Safety and Tolerability of Antianginal AUX-001

March 15, 2024

AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

Conformal Medical’s CLAAS® System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

March 13, 2024

Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices. The prospective, multicenter, randomized controlled study will enroll approximately 1,600 patients.

Bodyport Reports | Heart Failure Monitoring Technology Doubles Sensitivity for Predicting Events While Minimizing False Alerts Versus Standard of Care

March 6, 2024

“This should be welcome news for patient care teams because a greater prediction rate with fewer false alerts translates into more effective and efficient care,” said Corey Centen, founder, president, and chief technical officer at Bodyport. “What’s more, use of the Cardiac Scale and the Congestion Index is a seamless transition for clinicians and patients because it enhances, rather than replaces, the existing pathways built around weight monitoring. The lower alert rate should lead to workflow efficiencies because care teams—who are often feeling overly burdened by the large number of notifications and data flowing in—will spend less time responding to false alerts.”

Berlin Cures: BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

March 4, 2024

The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

BD Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

March 4, 2024

Dr. Sean Lyden, Chairman of the Department of Vascular Surgery at Cleveland Clinic and National Principal Investigator of the AGILITY Study said, “When we’re addressing advanced peripheral arterial disease, a self-expanding covered stent can play an important role. We need a stent that can track to the lesion, apposes the vessel wall and ultimately provides long-term durability. We’re excited to see how this technology performs.”

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

February 15, 2024

The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.

Medical Device News Magazine

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA